Welcome to our dedicated page for Hercules Capital news (Ticker: HTGC), a resource for investors and traders seeking the latest updates and insights on Hercules Capital stock.
Hercules Capital, Inc. provides senior secured venture growth loans to high-growth, venture capital-backed and institutional-backed companies, with an emphasis on technology and life sciences industries. Its updates commonly address debt and equity commitments, loan fundings, portfolio-company financings, net investment income, net asset value, leverage, available liquidity and recurring cash distributions.
Hercules also reports developments involving credit ratings, annual meeting and proxy matters, executive leadership, and its asset management activity through Hercules Adviser LLC and related Adviser Funds. The company’s common stock trades on the NYSE under HTGC, and its retail notes trade under HCXY.
Hercules Capital (NYSE: HCXY) declared a $0.47 per share total cash distribution for Q4 2025, comprising a $0.40 base and a $0.07 supplemental.
Record date is February 25, 2026 and payment date is March 4, 2026. The company said 100% of Q4 distributions derived from current and accumulated earnings and profits, and QII for 2025 distributions is 78.54%.
Hercules Capital (NYSE: HTGC) priced an underwritten public offering of $300.0 million aggregate principal amount of 5.350% unsecured notes due February 10, 2029.
The notes bear interest at 5.350% payable semiannually, are expected to settle on February 10, 2026, and proceeds are planned to fund investments, repay secured indebtedness and for general corporate purposes.
Hercules Capital (NYSE: HCXY) scheduled its fourth-quarter and full-year 2025 results release and conference call for Thursday, February 12, 2026. Results will be released after market close and a conference call will follow at 2:00 p.m. PT / 5:00 p.m. ET.
The live webcast and archived replay will be available on the Investor Resources page at investor.htgc.com. Domestic and international dial‑in numbers are provided, and callers should reference conference ID HTGCQ425.
Savara (Nasdaq:SVRA) amended its loan and security agreement with Hercules Capital (NYSE:HTGC) to make up to $75 million of additional debt available upon U.S. FDA approval of MOLBREEVI, an investigational therapy for autoimmune pulmonary alveolar proteinosis.
Combined with a previously announced $75 million royalty financing, the company would have access to approximately $150 million of non-dilutive capital to support a potential MOLBREEVI launch. Savara resubmitted the MOLBREEVI BLA in December 2025, is targeting potential approval in 3Q 2026 if Priority Review is granted, and expects to file EU/UK MAA by end of 1Q 2026.
enGene (Nasdaq: ENGN) amended its loan agreement with Hercules Capital to provide up to $125 million of debt financing, including $25 million funded at close and up to $100 million in additional tranches. The facility is non-dilutive, supports a planned BLA filing for detalimogene in H2 2026 and a potential commercial launch in 2027, and requires repayment of principal and accrued interest on or before January 1, 2030. Three $75 million of milestone-linked tranches and a discretionary final $25 million tranche complete the arrangement.
Compass Pathways (Nasdaq: CMPS) announced the U.S. FDA has accepted its IND for COMP360 in PTSD, enabling initiation of a Phase 2b/3 (COMP202) trial with a 12-week blinded Part A and 40-week open-label Part B; the primary endpoint is change in CAPS-5 at Week 8. Compass said prior Phase 2 open-label PTSD data showed rapid, durable symptom improvement (published September 2025). The company also reviewed commercial readiness for COMP360 in TRD and disclosed planned data timing: second half of Q1 2026 for combined COMP006/COMP005 readouts and COMP006 Part B 26-week data expected early Q3 2026. Financially, Compass amended a Hercules loan to up to $150M with $50M drawn, extended interest-only through at least January 5, 2029, and extended maturity to January 5, 2031.
Hercules Capital (NYSE: HCXY) said members of its executive management team will participate in the Citizens Financial Services Conference in New York on Tuesday, November 18, 2025.
Management availability includes participation in the conference and one-on-one meetings, which can be arranged through Citizens Financial Services.
Hercules Capital (NYSE: HTGC) reported record third-quarter and year‑to‑date activity for 2025, with Q3 total debt and equity commitments of $846.2M and record Q3 fundings of $504.6M. Year‑to‑date through Q3, commitments reached $2.87B and fundings $1.75B. Q3 investment income was $138.1M and Q3 net investment income (NII) was $88.6M or $0.49 per share, covering 122% of the base cash distribution.
Balance-sheet highlights: net GAAP leverage 98.2%, net regulatory leverage 82.3%, over $1.0B of available liquidity, undistributed earnings spillover of $146.2M ($0.80 per ending share), approximately $5.5B AUM (+20.7% YoY), and a Moody’s upgrade to Baa2.
Hercules Capital (NYSE:HCXY) declared a $0.47 per share total cash distribution for Q3 2025, composed of a $0.40 base distribution and a $0.07 supplemental distribution. The record date is November 12, 2025 and the payment date is November 19, 2025.
The Board maintains a variable distribution policy targeting distributions that approximate 90%–100% of taxable quarterly income and may pay supplemental amounts to distribute annual taxable income in the year earned. Of distributions declared for the quarter ended September 30, 2025, 100% were derived from current earnings and profits. Year-to-date Qualified Interest Income (QII) for 2025 distributions is 79.05%.
Hercules Capital (NYSE: HCXY) announced it reached $25.0 billion in total cumulative debt commitments since its first origination in October 2004, as of October 27, 2025. The company reported a 21-year 41.5% compound annual growth rate in cumulative commitments and highlighted key scale metrics including ~5.5 billion in assets under management (AUM) as of September 30, 2025, more than 700 portfolio companies, >1,000 venture/private equity sponsors, and over 270 IPO or M&A liquidity events.
The announcement credits its investment team, underwriting discipline, and partnerships for the milestone.